top of page
CALADRIO
PROSPECTIVE EVALUATION OF MICROBIOME AS A POTENTIAL PREDICTIVE FACTOR FOR IMMUNOTHERAPY IN LUMINAL-LIKE BREAST CANCER WITHIN THE KELLY CLINICAL STUDY
CLINICAL TRIAL DETAILS
THE CALADRIO PROJECT IS A SUB-STUDY OF THE KELLY TRIAL (MEDOPP127, EUDRACT#: 2016-004513-27, NCT03222856) WITH THE AIM OF CHARACTERIZING THE MICROBIOME AS A POTENTIAL PREDICTIVE FACTOR OF RESPONSE TO ANTI-PD-1 IMMUNOTHERAPY PEMBROLIZUMAB IN PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES. THE CALADRIO SUBSTUDY ASSESSES THE IMPACT OF GUT AND ORAL MICROBIOTA ON THE CLINICAL OUTCOME OF PATIENTS FROM THE KELLY TRIAL.
-----
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
BREAST
11
28
N/A
Spain
Analysis
TRIAL OVERVIEW
PRESS RELEASE
-----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
----
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page